What is the present valuation and projected CAGR of the trypsin-edta solution for cell dissociation market?
The trypsin-EDTA solution for cell dissociation market size has grown strongly in recent years. It will grow from $1.21 billion in 2024 to $1.33 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increasing demand for efficient cell dissociation, rapid expansion of the biopharmaceutical sector, rise in cancer research, growing demand for regenerative medicine and stem cell research, increase in the number of academic and research institutions.
The trypsin-EDTA solution for cell dissociation market size is expected to see strong growth in the next few years. It will grow to $1.87 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing focus on personalized medicine and targeted therapies, growth in biopharmaceutical production, increase the use of Trypsin-EDTA solutions in cell culture processes, rise in funding and initiatives for cancer research, demand for high-quality cell dissociation reagents. Major trends in the forecast period include use of animal-free and recombinant trypsin solutions, automated and high-throughput cell culture systems, use of serum-free media and supplements in cell culture, development of 3D cell culture and organoid models, regulatory and quality compliance in biopharmaceutical and clinical research.
Get Your Free Sample of The Global Trypsin-EDTA Solution For Cell Dissociation Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20667&type=smp
What key drivers have fueled the trypsin-edta solution for cell dissociation market’s development over the years?
The rising prevalence of chronic diseases is expected to propel the growth of the trypsin-EDTA solution for cell dissociation market going forward. Chronic diseases are long-lasting health conditions that persist for extended periods, often for a lifetime, and typically require ongoing medical management, such as diabetes, heart disease, and chronic respiratory conditions. Chronic diseases are rising due to factors such as aging populations, increased prevalence of risk factors like poor diet and physical inactivity, and advances in medical technology that lead to longer detection and management of these conditions. Trypsin-EDTA solution is used for cell dissociation in chronic disease research to effectively detach and harvest cells from tissues or cultures for further analysis or therapeutic application. For instance, in February 2024, according to a report published by the World Health Organization (WHO), a Switzerland-based intergovernmental organization, approximately 20 million new cancer cases were reported in 2022, along with 9.7 million deaths. By 2050, the number of new cancer cases is projected to rise to over 35 million, representing a 77% increase from the 2022 figures. Therefore, the rising prevalence of chronic diseases is driving the growth of the trypsin-EDTA solution for cell dissociation market.
Trypsin-EDTA Solution For Cell Dissociation Market Driver: Rising Demand For Personalized Medicine Fuels Growth Of Trypsin-EDTA Solution For Cell Dissociation Market
The growing demand for personalized medicine is expected to drive the growth of the Trypsin-EDTA solution for cell dissociation market going forward. Personalized medicine is a medical approach that tailors treatment and healthcare decisions to the individual characteristics, needs, and genetic profile of each patient. The growing demand for personalized medicine is driven by advancements in genomics, targeted therapies, and the increasing prevalence of chronic diseases that require more precise treatment approaches. Trypsin-EDTA solution for cell dissociation plays a role in personalized medicine by enabling efficient cell culture and manipulation, which is essential for research and development in cell-based therapies and regenerative medicine. For instance, in February 2024, according to Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, up from six in 2022. The newly approved personalized treatments for 2023 also include seven cancer drugs and three for other diseases and conditions. Therefore, the growing demand for personalized medicine is driving the growth of the Trypsin-EDTA solution for cell dissociation market.
What is the segmentation for the trypsin-edta solution for cell dissociation market?
The trypsin-EDTA solution for cell dissociation market covered in this report is segmented –
1) By Type: 0.25% Solution, 0.05% Solution
2) By Distribution Channel: Online Sales, Direct Sales, Retail
3) By Application: Insulin Manufacturing, Vaccines Manufacturing, Cell Culture, Other Applications
Subsegments:
1) By 0.25% Solution: General Cell Culture, Adherent Cell Lines, Suspension Cell Lines, Tissue-Derived Cells
2) By 0.05% Solution: Gentler Dissociation for Sensitive Cells, Primary Cell Cultures, Stem Cell Cultures, Short-Term Cell Cultures
Order your report now for swift delivery
Who are the most influential companies in the trypsin-edta solution for cell dissociation market?
Major companies operating in the trypsin-EDTA solution for cell dissociation market are Thermo Fisher Scientific Inc., Merck KGaA, GE Healthcare, Corning Incorporated, Lonza Group AG, VWR International LLC, Sartorius AG, STEMCELL Technologies Inc., Miltenyi Biotec B.V. & Co. KG, MP Biomedicals LLC, American Type Culture Collection (ATCC), Cyagen Biosciences Inc., HiMedia Laboratories Private Limited, FUJIFILM Irvine Scientific Inc., Nacalai Tesque Inc., Creative Dynamics Inc., PromoCell GmbH, Biological Industries Israel Beit Haemek Ltd., Worthington Biochemical Corporation, Capricorn Scientific GmbH, PAN-Biotech GmbH, Cell Applications Inc., Innovative Cell Technologies Inc., Wisent Bioproducts Inc., ZenBio Inc
What are the top industry trends projected to impact the trypsin-edta solution for cell dissociation market?
Major companies operating in the trypsin-EDTA solution for cell dissociation are developing innovative products, such as animal-based ECM dissociation solutions, to gain a competitive edge in the market. Animal-based ECM dissociation solutions are enzymatic or chemical formulations derived from animal sources used to break down extracellular matrix components and facilitate the detachment of cells from tissue or culture surfaces. For instance, in February 2023, a TheWell Bioscience, US-based biomedical technology company, launched the VitroGel Organoid Recovery Solution. The VitroGel Organoid Recovery Solution offers a groundbreaking advancement by enabling rapid and efficient recovery of organoids from both animal-based extracellular matrix (ECM) and synthetic VitroGel hydrogels. It achieves complete dissociation of animal-based ECM in just 2 minutes, with the entire cell harvesting process completed in only 15 minutes, a significant improvement compared to the leading solution that takes over 60 minutes. Designed for high-quality, intact organoid recovery, this solution provides superior yields, cell viability, and quality for passaging, cryopreservation, or biochemical analysis. Additionally, it operates at room temperature, eliminating the need for heat or cooling equipment and facilitating full lab automation for high-throughput organoid production.
What are the major regional insights for the trypsin-edta solution for cell dissociation market, and which region holds the top position?
North America was the largest region in the trypsin-EDTA solution for cell dissociation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the trypsin-EDTA solution for cell dissociation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Trypsin-EDTA Solution For Cell Dissociation Market Report 2025 Offer?
The trypsin-edta solution for cell dissociation market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Trypsin-EDTA solution is a cell dissociation reagent that merges trypsin, an enzyme that degrades proteins, with EDTA, a chelating agent that sequesters calcium ions, to detach adherent cells from culture vessel surfaces for subsequent processing or analysis. It is used for cell dissociation because it effectively breaks down proteins and disrupts cell adhesion, allowing for the detachment and harvesting of cells from culture surfaces.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20667
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
